Form 4 for ABBV AbbVie
Accepted 2022-02-22 00:00:00 ET · period of report 2022-02-17 · accession 0001179110-22-001506 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-02-22 | 2022-02-17 | ABBV | GONZALEZ RICHARD A | COB, CEO, Dir | A - Grant | $0.00 | +232.1K | 539.6K | +75% | $0 |
| D | 2022-02-22 | 2022-02-18 | ABBV | GONZALEZ RICHARD A | COB, CEO, Dir | A - Grant | $0.00 | +157.6K | 157.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.01 par value | 2022-02-17 | A | A | 34,937 | $0.00 | 574,529 | D | — | — | (F3) Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. |
| 2 | Common | Common Stock, $0.01 par value | 2022-02-17 | A | A | 34,146 | $0.00 | 608,675 | D | — | — | (F4) Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. |
| 3 | Common | Common Stock, $0.01 par value | 2022-02-17 | A | A | 133,889 | $0.00 | 510,486 | D | — | — | (F1) Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. |
| 4 | Common | Common Stock, $0.01 par value | 2022-02-17 | A | A | 29,106 | $0.00 | 539,592 | D | — | — | (F2) Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. |
| 5 | Derivative | Option (Right To Buy) | 2022-02-18 | A | A | 157,618 | $0.00 | 157,618 | D | $144.54 · 2023-02-17 to 2032-02-16 | 157,618 Common Stock | (F6) Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 52,540 on February 17, 2023, 52,539 on February 17, 2024, and 52,539 on February 17, 2025. |